A novel anti-influenza combined therapy assessed by single cell RNA-sequencing

To develop a novel treatment against influenza, we combined virucidal sialylated cyclodextrins with interferon lambda and demonstrated, in human airway epithelia, that the two compounds inhibit the replication of a clinical H1N1 strain more efficiently when administered together rather than alone. We investigated the mechanism of action of the combined treatment by single cell RNA sequencing analysis and found that both the single and combined treatments impair viral replication to different extents across distinct epithelial cell types. We also showed that each cell type comprises multiple sub-types, whose proportions are altered by H1N1 infection, and assess the ability of the treatments to restore them. Overall design: Reconstituted human airway epithelia infected with Influenza A and treated with cyclodextrins, interferon lambda or both. UPDATE: [Mar-22-2024] The Sample titles and characteristics were corrected. The associations of the raw data and processed data files with the Samples (GSMxxx) did not change.

为研发抗流感新型治疗手段，我们将杀病毒唾液酸化环糊精与λ干扰素（interferon lambda）联用，并在人类气道上皮细胞模型中证实：相较于单独给药，二者联合使用可更高效地抑制临床H1N1毒株的复制。我们通过单细胞RNA测序（single cell RNA sequencing）分析探究了联合疗法的作用机制，发现单一疗法与联合疗法在不同上皮细胞亚型中对病毒复制的抑制程度存在差异。此外我们还证实，每种细胞类型包含多种亚型，其比例会因H1N1感染而发生改变，并评估了各疗法对该亚型比例的恢复能力。

总体实验设计：经甲型流感病毒（Influenza A）感染，并分别给予环糊精、λ干扰素或二者联合处理的重组人类气道上皮细胞。

更新说明：[2024年3月22日] 已修正样本标题及特征信息。原始数据与处理后数据文件与样本（GSMxxx）的关联关系未发生改变。